Our translational lab group is dedicated to advancing the understanding and treatment of Parkinson’s Disease (PD) and Amyotrophic lateral sclerosis (ALS) through rigorous observational and interventional clinical trials. By bridging the gap between laboratory research and clinical application, we aim to develop more effective therapies and improve patient outcomes. Our trials are carefully designed to test the efficacy and safety of new treatments, providing critical data that guide therapeutic strategies and enhance the quality of life for individuals affected by these challenging neurological disorders.
Ongoing Research Focus Areas:
Characterizing Microbiome Changes in People with Parkinson’s Disease and Amyotrophic Lateral Sclerosis
- This study undertakes a comprehensive analysis of microbiome alterations in individuals with Parkinson’s Disease (PD) and Amyotrophic lateral sclerosis (ALS) compared to age-matched healthy controls. We aim to identify correlations between harmful microbiome metabolites, aggregated alpha-synuclein load, and immune markers in both the gut and peripheral tissues. Our objective is to validate new biomarkers that can improve early diagnosis and monitor disease progression in PD and ALS, facilitating more tailored and effective interventions.
Targeting the Gut Microbiome for the Treatment of Parkinson’s Disease and Amyotrophic Lateral Sclerosis
- This project explores the potential of manipulating the gut microbiome as a therapeutic strategy for Parkinson’s Disease (PD) and Motor Neuron Disease (MND). By identifying and analysing pathogenic bacterial species and strains elevated in patients with these conditions compared to age-matched healthy controls, we aim to elucidate the microbiome’s impact on the progression of these neurodegenerative diseases. The insights gained will guide the development of innovative microbiome-targeted therapies aiming to halt or reverse disease mechanisms.
Chemical Exposures in People with Parkinson’s Disease
- This project investigates the relationship between chemical exposures and Parkinson’s Disease. We are examining the types and levels of various environmental and occupational chemicals that individuals with PD are exposed to, compared to those without the disease. The findings will help to identify potential environmental risk factors and contribute to the development of preventive strategies and therapeutic interventions.
If you’re interested in participating in any of our studies or would like more information about our clinical research efforts, please register in our database by completing this survey: QUT_PDtrials, or feel free to email us at PDclinicaltrials@qut.edu.au. We look forward to hearing from you!